Sodium Aescinate Alleviates Neuropathic Pain in Rats by Suppressing the TLR4/NF KB Pathway Activation after Paclitaxel Chemotherapy

Background: Emerging evidence suggests that chemotherapy-induced peripheral neuropathy (CIPN) is a significant side effect of chemotherapeutic drugs. Many experiments have proved sodium aescinate (SA) has definite pharmacological effects such as anti-infection, anti-exudation, anti-edema, anti-tumor well neuroprotection, and the drug are mild. However, no study explored whether SA involved in analgesic paclitaxel (PAC) induced neuropathic pain rats. Methods: Rats were given an intraperitoneal injection PAC (2.5 mg/Kg intraperitoneally on days 1, 3, 5, 7), while 25 mg/kg was administered daily for 14 consecutive days. The mechanical withdrawal threshold (MWT) thermal latency (TWL) rats examined experimental 7, 11, 14. All sacrificed day 15 experiment, L4-6 spinal cords removed. Subsequently, immunohistochemistry, HE staining, ELISA, RT-qPCR, Western blotting applied to evaluate cytoskeletal protein expression (NF-L NF-M), nerve structural integrity, proinflammatory factor contents (TNF-α, IL-1β, IL-6), content TLR4/NF-κB pathway, respectively. Results: After developed behaviors, multiple injections rendered with elevated MWT TWL values, decreased NF-L NF-M cord, materially downregulated factors, reduced amounts TLR4 p-NF-κB levels. Conclusions: results present preliminarily indicate CIPN by injection, mechanism may be related blocking signaling inhibiting alleviating disorders.